Publication Year

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Jensen IS, Wu C, Fan W, Lodise T, Nicolau, DP, DuFour S, Cyr PL, et al. 2016. Use of oritivancin in moderate-severe ABSSSI patients requiring IV antibiotics: US hospital budget impact analysis. J Manag Care Spec Pharm 22(6):752-64; doi: 10.18553/jmcp.2016.22.6.752.

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, et al. 2016. Use of oritavancin in acute bacterial skin and skin structure infection patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016 36(2):157-68; doi: 10.1007/s40261-015-0365-8.

Sacks NC, Cabral HJ, Pizer SD, Burgess JF. 2016. Myopic and forward looking behavior in branded oral anti-diabetic consumption: An example from Medicare Part D. Health Econ, May.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246 [abstract].

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611 [abstract].

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

Cetin K, Callaghan F, Fryzek JP, Bylsma LC, Bezold C, Mehta B. Safety and Efficacy/Effectiveness of Second-line Treatments in Patients with Immune Thrombocytopenia: A Systematic Review of the Literature. Presented at the Thrombosis & Hemostasis Summit of North America 2016, April 14-16, 2016, Chicago, IL.